Clinical Trials Directory

Trials / Completed

CompletedNCT02650219

Auto-antibodies Prevalence and CD1 Role in Gaucher Disease

Prevalence of Autoantibodies in the Gaucher Disease and the Role of CD1 Molecules in Immune Manifestations of This Disease

Status
Completed
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Hospital St. Joseph, Marseille, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Hypergammaglobulinaemia is frequently observed in type 1 Gaucher disease (GD1), being either polyclonal or monoclonal gammopathies. Polyclonal hypergammaglobulinemia may be related to the presence of autoantibodies. The clinical significance of such antibodies is questioned in Gaucher disease (GD), as some cases of immunologic thrombocytopenia and autoimmune hemolytic anemia have also been reported. Objectives: To evaluate the prevalence of autoantibodies and autoimmune diseases in GD1 patients, we conducted a multicenter national study. The investigators investigated whether there was a link between splenectomy, genotype, therapeutic options and the presence of these autoantibodies.They also investigated whether there was a correlation with some clinical manifestations of GD1

Conditions

Interventions

TypeNameDescription
GENETICgenetic analyses

Timeline

Start date
2010-01-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2016-01-08
Last updated
2016-03-23
Results posted
2016-01-08

Locations

11 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02650219. Inclusion in this directory is not an endorsement.